Epigenetic inactivation of CHFR in nasopharyngeal carcinoma through promoter methylation

Molecular Carcinogenesis

Volumn 43, Issue 4, 2005, Pages 237-245

  Cheung, Hiu Wing ^a   Ching, Yick Pang ^a   Nicholls, John M ^a   Ling, Ming Tat ^a   Wong, Y C ^a   Hui, Nick ^a   Cheung, Annie ^a   Tsao, Sai Wah ^a   Wang, Qi ^a   Yeun, P W ^a   Lo, K W ^b   Jin, Dong Yan ^a   Wang, Xianghong ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

CHFR; Nasopharyngeal carcinoma; Promoter hypermethylation

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; MESSENGER RNA;

ADULT; ARTICLE; BREAST CANCER; CARCINOMA IN SITU; CHFR GENE; CHROMOSOMAL INSTABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; CYTOGENETICS; DNA METHYLATION; EPIGENETICS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MALE; MITOSIS; NASOPHARYNX; NASOPHARYNX CARCINOMA; OVARY CANCER; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; TUMOR XENOGRAFT;

CELL CYCLE PROTEINS; CELL LINE, TUMOR; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MALE; NASOPHARYNGEAL NEOPLASMS; NEOPLASM PROTEINS; PROMOTER REGIONS (GENETICS); RNA, MESSENGER;

EID: 23644441130     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/mc.20106     Document Type: Article

References (42)

1. Niedobitek G, Agathanggelou A, Nicholls JM. Epstein-Barr virus infection and the pathogenesis of nasopharyngeal carcinoma: Viral gene expression, tumour cell phenotype, and the role of the lymphoid stroma. Semin Cancer Biol 1996;7:165-174.
2. Lo KW, Teo PM, Hui AB, et al. High resolution allelotype of microdissected primary nasopharyngeal carcinoma. Cancer Res 2000;60:3348-3353.
3. Hui AB, Lo KW, Leung SF, et al. Detection of recurrent chromosomal gains and losses in primary nasopharyngeal carcinoma by comparative genomic hybridisation. Int J Cancer 1999;82:498-503.
4. Huang DP, Ho JH, Chan WK, Lau WH, Lui M. Cytogenetics of undifferentiated nasopharyngeal carcinoma xenografts from southern Chinese. Int J Cancer 1989;43:936-939.
5. Huang DP, Ho JH, Poon YF, et al. Establishment of a cell line (NPC/HK1) from a differentiated squamous carcinoma of the nasopharynx. Int J Cancer 1980;26:127-132.
6. Yao KT, Zhang HY, Zhu HC, et al. Establishment and characterization of two epithelial tumor cell lines (HNE-1 and HONE-1) latently infected with Epstein-Barr virus and derived from nasopharyngeal carcinomas. Int J Cancer 1990; 45:83-89.
7. Mitelman F. Catalog of chromosome aberrations in cancer. New York: Wiley-Liss; 1994.
8. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature 1997;386:623-627.
9. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998;396:643-649.
10. Bharadwaj R, Yu H. The spindle checkpoint, aneuploidy, and cancer. Oncogene 2004;23:2016-2027.
11. Jallepalli PV, Lengauer C. Chromosome segregation and cancer: Cutting through the mystery. Nat Rev Cancer 2001; 1:109-117.
12. Wassmann K, Benezra R. Mitotic checkpoints: From yeast to cancer. Curr Opin Genet Dev 2001;11:83-90.
13. Michel LS, Liberal V, Chatterjee A, et al. MAD2 haploinsufficiency causes premature anaphase and chromosome instability in mammalian cells. Nature 2001;409:355-359.
14. Wang X, Jin DY, Wong YC, et al. Correlation of defective mitotic checkpoint with aberrantly reduced expression of MAD2 protein in nasopharyngeal carcinoma cells. Carcinogenesis 2000;21:2293-2297.
15. Cahill DP, Lengauer C, Yu J, et al. Mutations of mitotic checkpoint genes in human cancers. Nature 1998;392:300-303.
16. Scolnick DM, Halazonetis TD. Chfr defines a mitotic stress checkpoint that delays entry into metaphase. Nature 2000; 406:430-435.
17. Kang D, Chen J, Wong J, Fang G. The checkpoint protein Chfris a ligase that ubiquitinates Plk1 and inhibits Cdc2 at the G2 to M transition. J Cell Biol 2002; 156: 249-259.
18. Chaturvedi P, Sudakin V, Bobiak ML, et al. Chfr regulates a mitotic stress pathway through its RING-finger domain with ubiquitin ligase activity. Cancer Res 2002;62:1797-1801.
19. Bothos J, Summers MK, Venere M, Scolnick DM, Halazonetis TD. The Chfr mitotic checkpoint protein functions with Ubc13-Mms2 to form Lys63-linked polyubiquitin chains. Oncogene 2003;22:7101-7107.
20. Toyota M, Sasaki Y, Satoh A, et al. Epigenetic inactivation of CHFR in human tumors. Proc Natl Acad Sci USA 2003;100:7818-7823.
21. Satoh A, Toyota M, Itoh F, et al. Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer. Cancer Res 2003;63:8606-8613.
22. Mizuno K, Osada H, Konishi H, et al. Aberrant hypermethylation of the CHFR prophase checkpoint gene in human lung cancers. Oncogene 2002;21:2328-2333.
23. Shibata Y, Haruki N, Kuwabara Y, et al. Chfr expression is downregulated by CpG island hypermethylation in esophageal cancer. Carcinogenesis 2002;23:1695-1699.
24. Honda T, Tamura G, Waki T, Kawata S, Nishizuka S, Motoyama T. Promoter hypermethylation of the Chfr gene in neoplastic and non- neoplasticgastricepithelia. Br J Cancer 2004;90:2013-2016.
25. Erson AE, Petty EM. CHFR-associated early G2/M checkpoint defects in breast cancer cells. Mol Carcinog 2004;39: 26-33.
26. Zhang S, Wu Y, Zeng Y, Zech L, Klein G. Cytogenetic studies on an epithelioid cell line derived from nasopharyngeal carcinoma. Hereditas 1982;97:23-28.
27. Cheng RY, Yuen PW, Nicholls JM, et al. Telomerase activation in nasopharyngeal carcinomas. Br J Cancer 1998;77: 456-460.
28. Glaser R, Zhang HY, Yao KT, et al. Two epithelial tumor cell lines (HNE-1 and HONE-1) latently infected with Epstein-Barr virus that were derived from nasopharyngeal carcinomas. Proc Natl Acad Sci USA 1989;86:9524-9528.
29. Lin CT, Wong CI, Chan WY, et al. Establishment and characterization of two nasopharyngeal carcinoma cell lines. Lab Invest 1990;62:713-724.
30. Tsao SW, Wang X, Liu Y, et al. Establishment of two immortalized nasopharyngeal epithelial cell lines using SV40 large T and HPV16E6/E7 viral oncogenes. Biochim Biophys Acta 2002;1590:150-158.
31. Bright RK, Vocke CD, Emmert-Buck MR, et al. Generation and genetic characterization of immortal human prostate epithelial cell lines derived from primary cancer specimens. Cancer Res 1997;57:995-1002.
32. Choo CK, Ling MT, Chan KW, et al. Immortalization of human prostateepithelial cells by HPV 16 E6/E7 open reading frames. Prostate 1999;40:150-158.
33. Rauh-Adelmann C, Lau KM, Sabeti N, Long JP, Mok SC, Ho SM. Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignait human ovarian, prostate, and breast cancer cell lines. Mol Carcinog 2000;28:236-246.
34. Wang X, Jin DY, Ng RW, et al. Significance of MAD2 expression to mitotic checkpoint control in ovarian cancer cells. Cancer Res 2002;62:1662-1668.
35. Tsao SW, Liu Y, Wang X, et al. The association of E-cadherin expression and the methylation status of the E-cadherin gene in nasopharyngeal carcinoma cells. Eur J Cancer 2003;39: 524-531.
36. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93: 9821-9826.
37. Wong CM, Lee JM, Ching YP, Jin DY, Ng IO. Genetic and epigenetic alterations of DLC-1 gene in hepatocellular carcinoma. Cancer Res 2003;63:7646-7651.
38. Doxsey S. Duplicating dangerously: Linking centrosorne duplication and aneuploidy. Mol Cell 2002;10:439-440.
39. Lingle WL, Barrett SL, Negron VC, et al. Centrosome amplification drives chromosomal instability in breast tumor development. Proc Natl Acad Sci USA 2002;99: 1978-1983.
40. Meraldi P, Honda R, Nigg EA. Aurora-A overexpression reveals tetraploidization as a major route to centrosome amplification in p53-/- cells. EMBO J 2002;21:483-492.
41. Wang X, Jin DY, Wong HL, Feng H, Wong YC, Tsao SW. MAD2-induced sensitization to vincristine is associated with mitotic arrest and Raf/Bcl-2 phosphorylation in nasopharyngeal carcinoma cells. Oncogene 2003;22:109-116.
42. Sudo T, Nitta M, Saya H, Ueno NT. Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Cancer Res 2004;64:2502-2507.